Analyst Price Target is $94.17
▲ +9.51% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $94.17, with a high forecast of $145.00 and a low forecast of $33.00. The average price target represents a 9.51% upside from the last price of $85.99.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in Beam Therapeutics.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.